Spire Corporation Reports Results For Fourth-Quarter And Year-End 2011

Spire Corporation ("Spire") (Nasdaq: SPIR), a diversified global company providing solar photovoltaic (PV) equipment and systems, biomedical processing services and optoelectronic components announced today revenues from continuing operations for the year ended December 31, 2011 of $61.6 million, a 22.8% decrease from $79.8 million in 2010. Net loss for the year ended December 31, 2011 was $1.5 million, or $0.18 per diluted share, compared to a net loss of $0.4 million, or $0.05 per diluted share, for the same period of 2010. These results include a gain on a settlement with a contract manufacturer of $1.4 million, net of a tax provision of $0.9 million, or $0.16 per diluted share for 2011. Fiscal year 2010 results include a gain on the sale of the assets of its Medical Device business to Bard Access Systems, Inc. of $1.6 million, net of a tax provision of $1.0 million, or $0.20 per diluted share. In addition, the Company recorded gains of $0.4 million and $1.9 million, respectively, on terminations of contracts for 2011 and 2010.

Spire’s revenues for the fourth-quarter ended December 31, 2011 were $19.5 million from continuing operations, an increase of 8.5% from $18.0 million in the fourth-quarter of 2010. Net income for the quarter was $1.6 million, or $0.19 per diluted share, compared to a net loss of $0.2 million, or ($0.02) per diluted share, for the fourth-quarter of 2010. Spire recorded net income from continuing operations of $0.2 million in the fourth-quarter of 2011 compared to a net loss from continuing operations of $0.2 million in the fourth-quarter of 2010.

Gross margin for fiscal year 2011 was $12.5 million, or 20.3% of revenue, compared to $14.7 million, or 18.4% of revenue for fiscal year 2010, representing an improvement in gross margin percentage of 10.3% over the prior year.

Net cash used in operating activities of continuing operations was $3.1 million for the year ended 2011 as compared to net cash used in operating activities of continuing operations of $2.4 million for the same period last year. At year-end 2011, Spire had cash and cash equivalents of $4.8 million as compared to $6.3 million at December 31, 2010.

If you liked this article you might like

Javelin Pharma, Spire: Volume Movers

Javelin Pharma, Spire: Volume Movers

TOR Minerals, Spire: Early Volume Plays

TOR Minerals, Spire: Early Volume Plays

U.S. Solar Firm Revenues Up, Profits Drop

U.S. Solar Firm Revenues Up, Profits Drop

Solar Equipment Firm Spire Slashing Staff

Solar Equipment Firm Spire Slashing Staff

Solar Winners: Huge Day for Spire

Solar Winners: Huge Day for Spire